Onco360(R) Has Been Selected as The National Specialty Pharmacy Partner for HYRNUO(R) (sevabertinib)
Onco360(R) Has Been Selected as The National Specialty Pharmacy Partner for HYRNUO(R) (sevabertinib) GlobeNewswire November 24, 2025 LOUISVILLE, Ky., Nov. 24, 2025 (GLOBE NEWSWIRE) — Onco360(R), the nation's leading independent Specialty Pharmacy, has been selected as the national pharmacy partner by Bayer Pharmaceuticals for HYRNUO(R) (sevabertinib). The Food and Drug Administration approved HYRNUO for the […]